About 10 weeks after it was approved, the Wegovy pill is now estimated to be part of the daily regimen of about 400,000 Americans. And the field of weight-loss treatment is on the verge of even more ...

Structure Therapeutics said its GLP-1 pill helped patients lose more than 16% of their body weight in a midstage trial, outperforming results reported for competing obesity drugs.

March 16 (Reuters) - Structure Therapeutics' oral obesity drug aleniglipron delivered up to 16.3% weight loss when compared with a placebo after 44 weeks of treatment in a mid‑stage study, it said on ...

One pill for obesity is already on the market, and more are on the way. But the injected drugs have key advantages.

Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare the drug’s efficacy to Eli Lilly’s orforglipron.

Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which ...

Add Yahoo as a preferred source to see more of our stories on Google. NEW YORK — A new pill form of the weight-loss drug Wegovy is now available to people in the United States, giving adults a daily ...

The weight-loss drug Wegovy is now being sold in pill form, an advancement that allows users to transition away from weekly injections. It's the first GLP-1 weight-loss medication to become available ...

Structure Therapeutics’ oral obesity drug elicited a placebo-adjusted weight loss of 16.3% at 44 weeks in a Phase 2 trial.

Uncrowned is a new destination for all things MMA, boxing, wrestling, and more, featuring Ariel Helwani. Yahoo Racing is powered by Motorsport Network, providing expert reporting, analysis, and ...